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Background: Transfemoral carotid artery stenting (CAS) has been associated with a high incidence of embolic phenomena
and silent brain infarction. The goal of this study was to compare the incidence of new ischemic cerebral lesions on
diffusion-perfusion magnetic resonance imaging (MRI) sequences after transcervical CAS performed with carotid flow
reversal vs stenting via transfemoral approach with distal filter protection.
Methods: During a 26-month period, 64 consecutive patients diagnosed with significant carotid stenosis by ultrasound
imaging were assigned to transcervical CAS with carotid flow reversal or a transfemoral approach with a distal filter. The
Rankin stroke scale was administered by an independent neurologist, and diffusion-weighted MRI (DW-MRI) studies
were performed <24 hours before and <24 to 48 hours after the procedure. DW-MRI studies were compared by two
neuroradiologists not involved in the study and blinded for time, clinical status, and treatment option. Hyperintense
DW-MRI signals found after the procedure were interpreted as postoperative ischemic infarcts. All patients were assessed
at 1, 6, and 12 months after the intervention.
Results: The distribution of demographic and pathologic variables was similar in both groups. All procedures were
technically successful, with a mean carotid flow reversal time of 22 minutes. Twenty-one (70%) and 23 patients (69.69%)
were symptomatic in the transcervical and transfemoral groups, respectively (P  .869). After intervention, new
postprocedural DW-MRI ischemic infarcts were found in four transcervical (12.9%) and in 11 transfemoral (33.3%)
patients (P  .03), without new neurologic symptoms. No major adverse events occurred at 30 days after the
intervention. All patients remained neurologically intact, without an increase in stroke scale scoring. All stents remained
patent, and all patients remained stroke-free during follow-up. In multivariate analysis, age (relative risk [RR], 1.022;
P< .001), symptomatic status (RR, 4.109; P< .001), and open-cell vs closed-cell stent design (RR, 2.01; P< .001) were
associated with a higher risk of embolization in the transfemoral group but not in the transcervical group.
Conclusions: These data suggest that transcervical carotid stenting with carotid flow reversal carries a significantly lower
incidence of new ischemic brain infarcts than that resulting from transfemoral CAS with a distal filter. The transcervical
approach with carotid flow reversal may improve the safety of CAS and has the potential to improve results in especially
vulnerable patients such as the elderly and symptomatic. ( J Vasc Surg 2012;56:1585-90.)
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sThe management of patients with carotid artery steno-
sis is evolving. A major concern with transfemoral carotid
artery stenting (CAS) with a distal filter for cerebral protec-
tion is its potential for cerebral embolization. The low
incidence of clinically apparent neurologic complications of
CAS is in stark contrast with the high incidence of silent
brain infarction demonstrated by diffusion-weighted mag-
netic resonance imaging (DW-MRI) after transfemoral
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http://dx.doi.org/10.1016/j.jvs.2012.05.107AS. Data from the only two recently published prospec-
ive trials comparing filter-protected vs unprotected trans-
emoral CAS demonstrated a higher incidence of new isch-
mic brain lesions after filter-protected transfemoral
AS.1,2
The results of CAS are clearly influenced by the access
oute and cerebral protection methods; however, these
actors have not been properly evaluated in any trial. The
isk of embolic complications with transfemoral carotid
tenting is related to instrumentation of the arch and prox-
mal supra-aortic trunks, crossing of the carotid lesion
ithout protection, and use of distal filter protection de-
ices of questionable benefit.
Transcervical CAS with flow reversal for cerebral pro-
ection has the potential advantage of reducing the inci-
ence of complications associated with transfemoral CAS
ith distal filter protection. This is suggested by DW-MRI
tudies after transcervical CAS with carotid flow reversal
howing a remarkably lower incidence of postprocedural
schemic brain infarcts compared with patients undergoing
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December 20121586 Leal et altransfemoral CAS with distal filter protection.3,4 This study
constitutes our institutional experience comparing trans-
cervical CAS with flow reversal vs CAS with transfemoral
filter protection.
METHODS
Study design. The study was designed as a single-
center, prospective, nonrandomized study in accordance
with the institutional board policies and regulations at the
Complejo Hospitalario de Toledo, Spain. It was approved
and monitored by the Institutional Review Board, and all
patients gave informed consent before enrollment.
Sample size calculations were based on previously re-
ported incidences of new ischemic lesions on postoperative
DW-MRI in CAS series. To have an 80% power of detect-
ing differences of at least 30% at a two-tailed level of 0.05,
34 patients were needed in each group. Enrollment was
performed between April 2008 and June 2009. The first
interventions were in 31 patients in the transcervical co-
hort, and they were the subject of a previous publication.3
Inclusion and exclusion criteria. All patients consid-
ered for the study had to be in a high-risk category for
carotid endarterectomy (CEA). Patients were invited to
participate if they had an extracranial internal carotid artery
stenosis 70% and a minimum distance of 5 cm from the
carotid bifurcation to the clavicle, as determined by an
ultrasound study. Exclusion criteria included allergy to
heparin, aspirin, clopidogrel, or iodinated contrast agents,
contraindication to MRI studies, intracranial bleeding,
hemorrhagic stroke or any stroke with mass effect demon-
strated on MRI or computed tomography4 weeks of the
index procedure, dementia or neurologic illness that might
confound the neurologic evaluation during the study, total
internal carotid artery occlusion, or common carotid artery
calcification with contraindication for puncture or sheath
placement.
Interventional technique. All patients were treated
preoperatively with aspirin and clopidogrel. All procedures
were performed by vascular surgeons experienced in CAS
and done under local anesthesia with clinical monitoring of
neurologic function.
Patients in the transfemoral group received heparin
(100 IU/kg) to achieve an activated clotting time of be-
tween 200 and 250 seconds. A 100-cm-long Guider Soft
Tip XF (Boston Scientific, Miami, Fla) or Ver 135 (Cordis,
Miami Lakes, Fla) guide catheter was used to introduce the
filter guidewire, crossing the stenosis, and the cerebral
protection device, a self-expanding Filter Wire EZ (Boston
Scientific), was deployed in the cervical portion of the
internal carotid artery. Predilation was done selectively with
a 3-mm percutaneous transluminal angioplasty balloon
catheter when the lesion lumen was estimated to be smaller
than the diameter of the stent delivery system. A self-
expandable Carotid Wallstent (Boston Scientific) or Pro-
tégé Rx (ev3 Endovascular, Minneapolis, Minn) was
mounted on the protection device guidewire and deployed
across the stenosis. The stent was dilated with an Ultrasoft
SV angioplasty balloon (5- to 6-mm diameter  20-mm dong; Boston Scientific). Atropine sulfate (1 mg) was intra-
enously administered before balloon inflations to prevent
arotid sinus stimulation. Then, the filter was removed.
Our technique for transcervical CAS with flow reversal
as been published before.5 Systemic anticoagulation with
ntravenous heparin (100 U/kg body weight) was con-
ucted before carotid occlusion and was not reversed with
rotamine at the completion of the procedure. The tech-
ique consists of a short incision above the edge of the
lavicle between the heads of the sternocleidomastoid mus-
le. A short segment of the common carotid artery and
ugular vein are dissected, and the common carotid artery is
ontrolled with a Rummel loop. Sheaths (8F) are placed in
he jugular vein and the common carotid artery and con-
ected to establish a carotid-to-jugular fistula. Flow reversal
s ascertained by arteriography. Then, under flow reversal, a
.014-inch guidewire is used to cross the carotid lesion,
nd the stenting is conducted under flow reversal in a
tandard fashion.
Both groups were prescribed a daily dose of acetylsali-
ylic acid (100 mg) and clopidogrel (75 mg) for 1 month
fter the procedure.
Neurologic evaluation. DW-MRI was acquired with
agittal T1 sequences, T2-weighted axial, fluid-attenuated
nversion recovery axial, and apparent diffusion coefficient
ap. In addition, T1-weighted axial and sagittal sequences
ere conducted after contrast administration. DW-MRIs
ere conducted24 hours before and 24 to 48 hours after
he procedure. Imaging was performed on a 1.5 T Signa
D unit (General Electric, Buckinhamshire, UK).
Preoperative and postoperative DW-MRIs were read
y two independent neuroradiologists unaware of the pa-
ient’s clinical status and blinded to the timing (preopera-
ive or postoperative) of the paired scans. Ischemic lesions
n the cerebral hemispheres, size, and location were re-
orded by each reader and compared with that of the
econd reader. Discrepancies were reviewed and reconciled.
All patients were evaluated by a neurologist before and
fter the procedure using the Rankin stroke scale and
ncluding sensory, motor, and autonomic testing. Neuro-
ogic deficits lasting24 hours were defined as stroke, and
hose lasting 24 hours were defined as transient ischemic
ttacks.
All patients were evaluated 30 days after surgery with a
linical assessment and carotid ultrasound imaging. Addi-
ional follow-up visits were performed at 6 and 12 months.
echnical success was considered when the stent was satis-
actorily deployed with30% residual stenosis in the target
egment.
Data analysis. The primary study end point was the
vidence of new ischemic lesions on postoperative DW-
RI studies. Continuous variables are expressed as the
ean and standard deviation (SD). Normality distribution
as assessed using the Kolmogorov-Smirnov test. Cate-
oric data were compared using the Fisher exact test and
re summarized as absolute frequencies and percentages.
omparison of continuous variables between cohorts was
one with the unpaired Student t-test. Statistical signifi-
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Volume 56, Number 6 Leal et al 1587cance was defined as two-sided P  .05. Statistical analysis
was conducted using SPSS 15.0 software (SPSS Inc, Chi-
cago, Ill).
We used binary regression models to compare MRI
outcome measures between treatment groups. Interactions
between the effect of treatment on the primary outcome
measure and selected variables (age, sex, operator, type of
stent used, symptomatic status) were investigated and ad-
justed for any significant imbalances in baseline character-
istics, if necessary.
RESULTS
Patient enrollment. Between April 2008 and June
2009, 64 consecutive patients were diagnosed with signif-
icant carotid stenosis by ultrasound imaging, and according
to the inclusion and exclusion criteria, 64 (58 men, 6
women) patients, with a mean age of 72.04 (SD, 10.97)
years, were enrolled. The procedures were done in two
separate periods. During the first part of the study, 31
patients underwent transcervical carotid stenting. During
the second part of the study, 33 patients underwent trans-
femoral CAS with distal filter protection.
Patient population. Comorbid conditions are sum-
marized in Table I. The two groups did not differ signifi-
cantly in demographics, symptomatic status, degree of ste-
nosis, and contralateral disease.
Procedural results. We used 45 Wallstents (Boston
Scientific, Natick, Mass) and 19 Protégé Rx (ev3 Endovas-
cular), without reaching a significant difference in the dis-
tribution of the types of stent (P  .647). Stent selection
was determined by lesion characteristics and surgeon pref-
erence. A closed-cell design was used whenever possible
and an open-cell one when size discrepancies between
common and internal carotid arteries or tortuosities were
found. Predilatation was performed in three patients in the
transcervical group and in two in the transfemoral group
(P  .694), using 3- to 4-mm diameter  2-cm-long
balloons inflated to 10 atm.
All procedures were technically successful without
(30%) residual stenosis. Mean surgical time was 46 (SD,
5.05) minutes in the transcervical group and 52 (SD,
10.14) minutes in the transfemoral group, which was not
significantly different (P  .324). Intolerance to carotid
flow reversal was not detected in any patient. After stenting,
there were no changes in the stroke scale in any patient in
either group. No strokes or transient ischemic attacks oc-
curred. There were no complications related to access site
in either group.
Neurologic evaluation and DW-MRI studies.
DW-MRI studies were done in all patients.Mean time from
the preoperative DW-MRI study and surgical procedure
was 13.5 (SD, 2.4) hours in the transcervical group and
11.6 (SD, 2.1) hours in the transfemoral group, without
significant differences between groups (P  .564). The
delay between procedures and the postoperative DW-MRI
study was 21.3 (SD, 1.5) hours in the transcervical group
and 20.4 (SD, 2.1) hours in transfemoral group (P  i354). Results from DW-MRI evaluation are summarized
n Table II.
New postprocedural DWI-MRI–detected cerebral
schemic lesions were found in four patients (12.9%) in the
ranscervical group. These four patients developed one
two patients), two (one patient), and five (one patient)
able I. Comorbid conditions
ariablea
Transcervical
(n  31)
Transfemoral
(n  33) P
ge, mean (SD) years 68.1 (10.7) 67.2 (10.01) .869
ex .346
Male 27 (87.09) 31 (93.94)
Female 4 (12.91) 2 (6.06)
ctogenarians 1 (3.23) 1 (3.03) .964
ypertension 24 (77.41) 20 (60.61) .146
iabetes mellitus 11 (35.48) 18 (54.55) .125
ypercholesterolemia 17 (54.84) 15 (45.45) .453
revious myocardial
infarction 7 (22.58) 4 (12.13) .267
urrent smokers 9 (29.03) 15 (45.45) .689
eripheral arterial
disease 5 (16.13) 4 (12.13) .644
resenting symptoms 21 (67.64) 23 (69.69) .869
Transient ischemic
attack 13 (41.93) 15 (45.45) .776
Major stroke 8 (25.81) 8 (24.25) .885
symptomatic 10 (32.26) 10 (30.03) .886
ignificant
contralateral ICA
disease 5 (16.13) 3 (9.68) .394
re-op Rankin, mean
(SD) score 0.6605 (1.14) 0.6745 (1.04) .305
arotid plaque
morphologyb
Type 1 2 (6.45) 3 (9.68) .694
Type 2 9 (29.03) 11 (35.49) .711
Type 3 9 (29.03) 8 (24.25) .306
Type 4 10 (32.26) 11 (35.49) .927
Type 5 1 (3.23) 0 (0) .972
CA, Internal carotid artery; SD, standard deviation.
Data are shown as number (%), unless stated otherwise.
Morphology was assessed according to echolucency criteria. Type 1: dom-
nantly echolucent; type 2: substantially echolucent with small areas of
chogenicity; type 3: dominantly echogenic with small areas of echolucency;
ype 4: uniformly echogenic; and type 5: not classified owing to acoustic
hadowing artifact.
able II. Results from diffusion-weighted magnetic
esonance imaging (DW-MRI) evaluation
ariable
Transcervical
(n  31)
No. (%)
Transfemoral
(n  33)
No. (%) P
atients with new
lesions
4 (12.90) 11 (33.33) .03
o. of new lesions 4 13 .02
ocalization of new
lesions
Ipsilateral 4 11 .03
Contralateral 0 2 .16schemic lesions, respectively. All lesions were subcortical,
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asymptomatic.
In the transfemoral group, new lesions were found in
11 of the 33 patients (33.3%) enrolled, one in nine patients
and two in the remaining two. Eleven ischemic lesions
(84.3%) were ipsilateral and two (15.7%) were contralat-
eral. All were 5 mm, localized in the white matter, and
asymptomatic. The difference in the incidence of new isch-
emic lesions in postoperative studies between the treatment
groups (12.9% vs 33.3%) was significant (P  .03).
The Rankin stroke scale did not deteriorate in any
patient. Postoperatively, the Rankin scale slightly improved
in the transcervical and transfemoral groups, although this
difference did not reach significance.
Evaluation of predictors of embolization. In the
multivariate analysis, none of the tested variables (age, sex,
operator, type of stent used, symptomatic status) reached
significance to predict the presence of embolization in the
postoperative DW-MRI studies.
Adjusting analysis by type of treatment, age (relative
risk [RR], 1.022, 95% confidence interval [95%CI], 1.021-
1.041; P  .001), recent symptomatic status (RR, 4.109;
95% CI, 1.74-9.65; P .001), and closed-cell vs open-cell
stent type (RR, 0.082; 95% CI, 0.019-0.359; P  .001)
were independent predictors of embolization in the trans-
femoral group but not in the transcervical group.
Follow-up. All patients were evaluated with neuro-
logic evaluation and carotid ultrasound imaging at 1 and 6
months, at 1 year, and yearly thereafter. Mean follow-up
time was 23.25months. No new neurologic events, deaths,
or admissions to the hospital occurred during the follow-up
period. The Rankin stroke scale remained unchanged in all
patients. According to the ultrasound evaluation, all stents
remained patent, with no signs of restenosis.
DISCUSSION
CAS is currently an accepted alternative treatment for
carotid stenosis. Although early case series and registries
reported low rates of periprocedural complications risk,6-11
recent large randomized trials comparing CAS with CEA
have yielded controversial results.12-14
The risk of stroke associated with CAS is clearly related
to embolic phenomena that occur during the intravascular
instrumentation of the aortic arch, supra-aortic trunks, and
carotid plaque itself throughout the procedure, as has been
demonstrated with transcranial Doppler monitoring.15
A more sensitive tool for the detection of periproce-
dural embolization producing acute cerebral ischemia dur-
ing CAS is MRI diffusion-perfusion imaging.16-19 Cyto-
toxic cell swelling that occurs as an immediate response to
neuronal ischemia causes an increase in the diffusion signal
that correlates with perfusion imaging results in the gener-
ation of hyperintense images corresponding to areas of
acute cerebral ischemia.20,21
Our single-center results are revealing. The existence of
a significant difference in the incidence of new ischemic
lesions on postoperative DWI-MRI between transcervical and transfemoral groups is very consistent with published
ata.
Distal filter use can be associated with internal carotid
rtery spasm, increased crossing profile for the initial wire
ccess, and technical misadventures in attempts to retrieve
he filter after stent deployment.22 The current generation
f antiembolic filters also have important limitations: First,
ommercially available filters have pore sizes of 100 to 150
m; meanwhile, high-volume microemboli from 60 m
ave been demonstrated in experimental models at all
tages of the procedure, including the initial wire passage.23
Second, the absence of neuroprotection creates a prob-
em during aortic arch manipulation, accessing the com-
on carotid artery, and while crossing the stenosis, which
re highly emboligenic maneuvers, according to research
onducted with continuous transcranial Doppler imag-
ng.24
Embolic events during aortic archmanipulation explain
he contralateral hemispheric lesions found in two of 11
atients with new lesions in the transfemoral group. Simi-
arly as in previously published CEA series and unlike in the
ransfemoral group, no contralateral hemispheric infarcts
ere found in the transcervical cohort.
In the four patients in whom new lesions were docu-
ented in the transcervical group, flow interruptions oc-
urred because the carotid sheath was dislodged during the
rocedure. All interruptions were due to movement and
xit of the carotid sheath by accidental manipulation in the
urgical field, needing to interrupt flow reversal, and in
ome cases, carotid artery clamping was required to rein-
roduce the sheath. Ensuring the stability of the arterial
heath is crucial to maintain a stable and constant flow
eversal. There are two maneuvers to achieve this: first,
xing the sheath to the patient’s skin, and second, routing
he sheath through a skin and a subcutaneous tunnel cre-
ted from the clavicle to the carotid sheath. As seen in our
esults, all patients with an unstable arterial access devel-
ped new lesions in postoperative DW-MRI, revealing the
ranscendency of this fact, which probably must be im-
roved in the technique.
The sensitivity in acute lesion detection varies among
ifferent MRI systems, so it is difficult to compare our
esults with those of other studies. However, the low 12.9%
ncidence in the transcervical group is comparable to the
est series of CEA and a great improvement over the results
f CAS with distal filters. The results of this work also
onfirm previously reported transcervical series.25 Based on
ur technique, a novel transcervical access and cerebral
mbolic protection system (MICHI Neuroprotection Sys-
em; Silk Road Medical Inc, Sunnyvale, Calif) has shown
imilar low DW-MRI rates.26
Our study has several limitations that should be ac-
nowledged. First, it is a nonrandomized single-center
xperience. Because of logistical difficulties, we defined two
ifferent and consecutive periods over time to develop a
onsecutive sampling, including every patient who met
nclusion and exclusion criteria. Randomization reduces
llocation bias, balancing both known and unknown prog-
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two intervention groups are comparable in all of the main
demographic and pathologic variables.
Second, we used DW-MRI to compare silent brain
infarcts occurring after the two different techniques, but
the real clinical relevance of postoperative DW-MR lesions
has yet to be clarified. The effect of these new hyperintense
signals that do not correlate with clinical events is still
unknown, and some of these lesions may disappear over
time.4,27 The long-term effect of these lesions may be
associated with an increased risk of dementia and cognitive
impairment,28 although this association is still uncertain.29
The need to surgically access both the common carotid
artery and jugular vein could be considered a drawback of
our technique. However, no wound complications oc-
curred in this study, and also, no cranial nerve injury has
been reported with this approach. Our technique focuses
on improving results of CAS and overcoming limitations of
transfemoral access and filters. Results regarding neuro-
logic complications, even asymptomatic, make this tech-
nique probably comparable to CEA, although the latter
continues to be the gold standard treatment of carotid
artery stenosis in most patients. However, CAS is undoubt-
edly a very welcome addition to our armamentarium. Some
of the main issues that appear to limit its usefulness and
applicability are probably cerebral embolization and cathe-
ter and device access to the target lesion. Transcervical CAS
with flow reversal overcomes limitations in access to the
lesion, and as shown in this study, also cerebral emboliza-
tion.
Age and symptomatic status are risk factors for peripro-
cedural cerebrovascular events in the subgroup analysis of
large trials.30 In our experience, age and symptomatic
status were risk factors for new embolization in the trans-
femoral group but not in the transcervical group. The safety
of CAS in octogenarian patients has been questioned in
several large trials. In the Carotid Revascularization Endar-
terectomy Versus Stenting Trial (CREST) study,31 patients
aged70 years who underwent stenting had fewer adverse
events—combined rate of death, stroke or myocardial in-
farction—than patients who underwent CEA.
A recent analysis examined the effect of age on the
CAS-to-CEA relative efficacy using proportional hazard
models.32 In this analysis, age acted as a treatment effect
modifier for the primary end point. For CAS, risk for the
primary end point increased with age, mainly by stroke
events as the primary contributor to the overall effect
modification.
The results of our study are consistent with recent data
that suggest that age by itself is associated in a weak but
significant way (RR, 1.022; 95% CI, 1.021-1.041; P 
.04), with an increased risk of embolization by DW-MRI
evaluation. However, this effect is only observed in the
transfemoral group and not in the transcervical group.
Similarly, symptomatic status is a strong predictor of
the presence of new ischemic lesions in postoperative MRI
studies (RR, 4.109; 95% CI, 1.74-9.65; P  .01) but only
in the transfemoral group. Comparative results betweenAS and CEA in the CREST study in symptomatic patients
id not reach significance, although the incidence of ad-
erse events was higher in the symptomatic group.
There are conflicting publications in the current litera-
ure about the influence of stent design on the outcome of
AS, and results of our work are also conflicting.33-37 No
ifferences were found between the two designs, consider-
ng all individuals, for the contribution of risk in the occur-
ence of new lesions in MRI studies, which is consistent
ith recent studies. However, the adjusted analysis by the
ype of procedure showed a slight but significant difference
n favor of closed-cell stents but only in the transfemoral
roup (RR, 0.082; 95% CI, 0.019-0.359; P  .001).
Results of regressionmodels predictingDW-MRI post-
perative lesions should be interpreted with caution, given
he small sample size and the small number of new lesions.
hese two main factors make this model relatively under-
owered to identify independent predictors of the study
utcome. However, the existence of worse prognostic data
n older patients, symptomatic patients, and CAS with
pen-cell stents only in the transfemoral group could be
ritical subgroups that benefit most from the use of the
ranscervical approach with flow reversal.
ONCLUSIONS
Our data strongly suggest that transcervical carotid
tenting with carotid flow reversal may produce a signifi-
antly lower incidence of cerebral embolization compared
ith conventional transfemoral carotid stenting procedures
ith distal filter protection. Age, recent symptomatic sta-
us, and stent design were significantly associated with a
igher incidence of new embolic lesions in the transfemoral
roup but not in the transcervical group.
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